Skip to main content
. Author manuscript; available in PMC: 2015 Nov 3.
Published in final edited form as: Curr Alzheimer Res. 2015;12(9):847–859. doi: 10.2174/156720501209151019105834

Figure 3. Treatment with ceramidase inhibitor ceranib-1, PKC activators 12-myristate 13-acetate (PMA) and diacylglycerol (DAG) decrease APP mRNA in ABCA2-overexpressing cells.

Figure 3

Cells were treated with increasing concentrations of ceranib-1 (A), PMA (B), or DAG (C) for 6 hours and total RNA was recovered from cell homogenates. Real-time PCR for relative APP mRNA was performed on total RNA and quantified as described in Methods. Results are the mean fold-change in APP mRNA expression in A2 cells compared to N2a cells ± SD of ≥ three experiments. Statistical significance was determined using the Student’s t test, p < 0.05.